Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib.

Andrew T KuykendallSomedeb BallBarbara MoraQianxing MoNajla Al AliMargherita Maffioli Giuseppe AuteriCamilla MazzoniGiuseppe Alberto Maria Palumbo Andrea DuminucoAnna LongoElena Maria Elli Francesco Passamonti Francesca Palandri Rami S Komrokji

Published in: JCO precision oncology (2024)

These findings suggest that serum albumin, a ubiquitously available laboratory value, has specific relevance in patients with MF and reflects therapeutic response to ruxolitinib.

Keyphrases

metabolic syndrome
combination therapy
newly diagnosed
skeletal muscle
weight loss